Q1 Earnings Forecast for Alto Neuroscience Issued By Wedbush

Alto Neuroscience, Inc. (NYSE:ANRO) – Analysts at Wedbush dropped their Q1 2025 earnings per share (EPS) estimates for Alto Neuroscience in a research note issued to investors on Wednesday, October 23rd. Wedbush analyst L. Chico now expects that the company will earn ($0.67) per share for the quarter, down from their prior forecast of ($0.53). Wedbush has a “Neutral” rating and a $4.00 price objective on the stock. The consensus estimate for Alto Neuroscience’s current full-year earnings is ($2.63) per share. Wedbush also issued estimates for Alto Neuroscience’s Q2 2025 earnings at ($0.69) EPS, Q3 2025 earnings at ($0.70) EPS, Q4 2025 earnings at ($0.72) EPS, FY2025 earnings at ($2.78) EPS, FY2026 earnings at ($2.24) EPS, FY2027 earnings at ($2.31) EPS and FY2028 earnings at ($2.61) EPS.

Alto Neuroscience (NYSE:ANRO) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.07.

A number of other equities analysts have also weighed in on the company. Rodman & Renshaw lowered Alto Neuroscience from a “buy” rating to a “neutral” rating in a research note on Wednesday, October 23rd. William Blair restated an “outperform” rating on shares of Alto Neuroscience in a research note on Tuesday, September 10th. Robert W. Baird reduced their price objective on shares of Alto Neuroscience from $32.00 to $10.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 23rd. Finally, RODMAN&RENSHAW lowered shares of Alto Neuroscience from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 23rd. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $24.40.

Alto Neuroscience Trading Up 5.8 %

Shares of ANRO stock opened at $4.37 on Monday. The company has a current ratio of 19.85, a quick ratio of 19.85 and a debt-to-equity ratio of 0.04. The stock has a fifty day simple moving average of $12.02 and a two-hundred day simple moving average of $12.34. Alto Neuroscience has a 52-week low of $3.93 and a 52-week high of $24.00.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ANRO. Federated Hermes Inc. raised its holdings in shares of Alto Neuroscience by 33.3% in the second quarter. Federated Hermes Inc. now owns 12,000 shares of the company’s stock worth $128,000 after buying an additional 3,000 shares during the period. Rhumbline Advisers purchased a new stake in Alto Neuroscience in the second quarter worth $113,000. Bank of New York Mellon Corp bought a new stake in shares of Alto Neuroscience during the second quarter worth $252,000. Bowie Capital Management LLC purchased a new stake in shares of Alto Neuroscience during the second quarter valued at $462,000. Finally, Zimmer Partners LP bought a new position in shares of Alto Neuroscience in the first quarter worth about $1,151,000.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.